Kara McKinley, PhD, principal faculty at HSCI, has been named one of the 2022 class of Packard Fellows for Science and Engineering. McKinley and 19 other innovative early-career scientists and engineers will each receive $875,000 over five years to pursue their research.
The Packard Fellowships for Science and Engineering are designed to encourage innovative, blue-sky thinking by providing maximum flexibility and support to...
Fernando Camargo recognized for pioneering scientific contributions and outstanding leadership
Fernando Camargo, Ph.D., has been named as the inaugural Regenerative Biology Endowed Chair by the Boston Children’s Hospital (BCH) Department of Pediatrics, in recognition of his pioneering scientific contributions and outstanding leadership. Camargo is a professor in the Harvard Department of Stem Cell and Regenerative Biology (HSCRB) and Harvard Medical School (HMS)...
AWARD AMOUNT Up to $100,000 for entire project period Project period not to exceed 2 years
POSTED DATE Wednesday, February 2, 2022
DEADLINE FOR APPLICATION Friday, March 4, 2022
ANTICIPATED AWARD DATE April 1, 2022
The Harvard Stem Cell Institute (HSCI) Cancer Program invites applications for pilot grants to be awarded for research in 2022. The intent is to provide resources for innovative projects dissecting stem/developmental programs in solid tumors that would help foster collaborations within the HSCI research community. This funding is for innovative, high-impact research projects. Multi-investigator, multi-institution proposals are encouraged; of specific interest to this funding cycle are proposals that dissect mechanisms that enable malignant stem cells to evade the immune system. Additionally, the applications should promote the Program mission: To identify critical genes and pathways that sufficiently distinguish cancer from normal stem cells and hence may serve as candidate targets for therapy.... Read more about Call for Proposals: 2022 HSCI Cancer Program Pilot Grants
Bone metastases are devastating developments of cancers that originate in other organs. In the case of metastatic prostate cancer, bone metastases represent an incurable, painful, and often deadly development, killing more than 30,000 American men every year. Unlike many other tumor types, metastatic prostate cancer responds poorly to immune-based therapies, but a new study published in Cancer Cell and originating in part from Harvard Stem Cell Institute (HSCI) labs, has uncovered a key mechanism for why such therapies fail to work, potentially leading the way to a breakthrough in the treatment of this devastating disease.... Read more about A new study illuminates the therapy resistance of metastatic prostate cancer
HSCI researchers create ON-OFF switches to better control CAR T cell activity
HSCI scientists have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has shown dramatic success in treating some advanced cancers, but...
HSCI Executive Committee member Carla Kim is a recipient of the Lung Cancer Discovery Award from the American Lung Association. The award recognizes Kim’s innovative lung cancer research that has the potential to improve patient care and help save lives.
“As our nation faces COVID-19, we have not only witnessed its toll on our health, but we have also seen how air pollution,...